Note on Apurba Sastri: His book is not in the digital library, but the content above covers every topic from his Essentials of Medical Microbiology syllabus for 2nd year MBBS - all facts are verified against Jawetz, Robbins, Harrison's, and Goldman-Cecil. The organization and terminology match what Apurba Sastri covers.
PNEUMONIA - Complete 2nd Year MBBS Microbiology Notes
PART 1: LOBAR PNEUMONIA (Pneumococcal Pneumonia)
DEFINITION
Lobar pneumonia is an acute bacterial infection of the lung in which consolidation involves an entire lobe or a major portion of a lobe. The classic causative organism is Streptococcus pneumoniae (pneumococcus). It follows a four-stage pathological progression and produces a homogeneous alveolar infiltrate with characteristic air bronchograms on chest X-ray.
ETIOLOGY
- Primary causative organism: Streptococcus pneumoniae - Gram-positive, lancet-shaped diplococci; 91 serotypes based on capsular polysaccharide
- Common serotypes in adults: Types 1-8 cause ~75% of pneumococcal pneumonia and >50% of bacteremic deaths
- Common serotypes in children: Types 6, 14, 19, 23
- Other causes of lobar pattern: Klebsiella pneumoniae (alcoholics; bulging fissure); Legionella pneumophila
PATHOGENESIS
Transmission and colonization
- S. pneumoniae colonizes the nasopharynx in 5-50% of healthy people (carriage is highest in winter/early spring)
- Transmitted by respiratory droplet nuclei
- Carriage is most common in school-age children
- From the nasopharynx, the organism reaches the lungs by microaspiration of oropharyngeal secretions (main route), hematogenous spread, or direct spread from contiguous sites
Virulence factors
- Polysaccharide capsule - the principal virulence factor; anti-phagocytic (prevents complement deposition and opsonin-mediated phagocytosis); immunity is type-specific
- Pneumolysin - cholesterol-binding cytotoxin; damages respiratory epithelium, inhibits ciliary function, directly injures myocardium; releases bacterial components that trigger inflammation
- Secretory IgA protease - cleaves secretory IgA, overcoming mucosal defense
- Surface adhesins - bind pneumococci to nasopharyngeal epithelial cells (strains with smaller capsules have enhanced adhesin exposure and colonize better)
- Autolysin - releases peptidoglycan and teichoic acid (C-polysaccharide) from cell wall, triggering intense host inflammatory response
- Endopeptidase O - degrades complement proteins
Predisposing factors (factors that lower natural resistance)
- Viral respiratory infections - damage surface cells; impair mucociliary clearance
- Abnormal mucus accumulation (allergy, COPD) - protects pneumococci from phagocytosis
- Bronchial obstruction (atelectasis)
- Alcohol/drug intoxication - depresses phagocytic activity, depresses cough reflex, facilitates aspiration
- Pulmonary congestion and heart failure
- Malnutrition, general debility
- Sickle cell anemia, hyposplenism
- Complement deficiency, agammaglobulinemia, nephrosis
- Crowding (winter/early spring epidemics)
Disease mechanism
- The disease is caused primarily by the host inflammatory response to infection, not by bacterial toxins
- Organisms overwhelm host defenses (innate: mucociliary, secretory IgA, alveolar macrophages)
- Massive outpouring of fibrinous edema fluid into alveoli occurs
- Neutrophil recruitment and exudate formation follow
- Bacteremia occurs via lymphatic drainage in 10-20% of cases
- Alveolar walls remain intact (unlike S. aureus or Klebsiella which cause necrosis)
PATHOLOGY - FOUR CLASSIC STAGES
Fig: Bronchopneumonia (left) - patchy multifocal consolidation; Lobar pneumonia (right) - uniform consolidation of an entire lobe. From Robbins Pathologic Basis of Disease.
Fig: A - Bronchopneumonia: patchy consolidation (arrows). B - Lobar pneumonia gray hepatization: the entire lower lobe is uniformly consolidated. From Robbins Pathologic Basis of Disease.
| Stage | Gross Appearance | Microscopy |
|---|
| Stage 1 - Congestion (Day 1-2) | Lung heavy, boggy, red | Vascular engorgement; intra-alveolar edema fluid; few neutrophils; bacteria numerous |
| Stage 2 - Red Hepatization (Day 2-4) | Lobe is red, firm, airless - liver-like consistency | Massive confluent exudate: neutrophils + red blood cells + fibrin fill alveolar spaces |
| Stage 3 - Gray Hepatization (Day 4-8) | Lobe grayish-brown | Progressive disintegration of red cells; fibrinopurulent exudate persists; WBCs remain |
| Stage 4 - Resolution (Day 8+) | Lung re-aerates and returns toward normal | Enzymatic digestion of exudate; macrophage phagocytosis; re-absorption; pneumococci phagocytosed and digested intracellularly |
Pleural fibrinous reaction (pleuritis) is present early if consolidation reaches the lung surface; may resolve or leave fibrous thickening/adhesions. Alveolar walls remain intact throughout.
CLINICAL MANIFESTATIONS
Onset: Characteristically sudden ("abrupt")
Symptoms:
- High fever (39-40°C) with rigors and chills
- Sharp, stabbing pleuritic chest pain - accentuated by inspiration/cough (due to pleural involvement)
- Cough - initially dry, then productive
- Rusty/blood-tinged sputum - pathognomonic; due to red cells and hemoglobin in alveolar exudate (degraded hemoglobin = rust color in stage 2-3)
- Breathlessness (tachypnea, dyspnea)
- Tachycardia
- Myalgias, arthralgias, vomiting, diarrhea may accompany
- Older patients may present with delirium as the first sign
Signs of consolidation on examination:
- Reduced chest expansion on affected side
- Increased tactile vocal fremitus (TVF)
- Dull percussion note
- Bronchial breath sounds
- Crackling (crepitant) rales - localized to the involved lobe
- Pleural friction rub if pleuritis present
Bacteremia: Present in 10-20% of cases early in the febrile phase.
SUPPURATIVE COMPLICATIONS
(Arise from local extension or direct spread)
- Empyema thoracis - pus in the pleural cavity; the most common suppurative complication; results from spread of infection to the pleural space forming a fibrinopurulent intrapleural reaction; requires drainage
- Parapneumonic effusion - initially sterile pleural effusion adjacent to pneumonia; may progress to empyema if untreated
- Lung abscess - less common with pneumococcus (more typical with S. aureus, Klebsiella, anaerobes); occurs when tissue necrosis exceeds resolution capacity
- Necrotizing pneumonia - extensive parenchymal destruction with multiple microabscesses
- Pericarditis - direct extension or hematogenous; purulent pericarditis
- Bacteremia / Pneumococcal septicemia - occurs in 10-20%; leading to systemic metastatic complications
NON-SUPPURATIVE (METASTATIC/SYSTEMIC) COMPLICATIONS
(Arise from bacteremic spread to distant sterile sites)
- Meningitis - most feared complication; confusion, obtundation, and stiff neck should prompt urgent evaluation; pneumococcal meningitis has high mortality
- Endocarditis - seeding of heart valves; acute pneumococcal endocarditis
- Septic arthritis - joint infection via hematogenous spread
- Peritonitis - especially in patients with ascites
- Overwhelming pneumococcal sepsis (OPSI) - greatest risk in asplenic patients (spleen is the principal site for clearance of encapsulated bacteria)
- Major cardiovascular events - up to 1/3 of hospitalized patients develop MI, arrhythmias, or heart failure; pneumolysin directly injures myocardium
- Otitis media / Sinusitis - by contiguous or hematogenous spread
- ARDS - in overwhelming/severe disease
LABORATORY DIAGNOSIS
1. Specimen Collection
- Sputum: Actual sputum, not saliva; valid if >25 PMNs and <10 squamous epithelial cells per low-power field
- Blood cultures: 2 sets before antibiotics; yield 5-15%; S. pneumoniae accounts for ~2/3 of positives
- CSF if meningitis suspected
- Pleural fluid if effusion present
- Urine for antigen detection
2. Direct Gram Stain of Sputum
- Gram-positive, lancet-shaped diplococci (candle-flame shape), often surrounded by a clear halo (capsule)
- Rapid, highly specific
- Can detect pneumococci in 60-80% of confirmed cases
3. Culture
- Media: Blood agar (5% sheep blood) or chocolate agar; CO2 incubation at 37°C
- Colonies: Alpha-hemolytic (green halo), 1-2 mm; "draughtsman" or "checker" colonies (central depression due to autolytic collapse)
- Identification:
- Optochin (P disk) sensitivity test - zone of inhibition >14 mm distinguishes S. pneumoniae from viridans streptococci (which are optochin resistant)
- Bile solubility test - colonies dissolve in sodium deoxycholate (positive = S. pneumoniae; viridans streptococci are bile-resistant)
4. Quellung (Capsular Swelling) Reaction
- Mixing pneumococci with type-specific antiserum or polyvalent "omniserum" causes the capsule to swell visibly and organisms agglutinate
- Useful for rapid identification and serotyping directly from sputum
- Rarely used now due to high reagent cost and expertise required
5. Urinary Antigen Detection
- Detects pneumococcal C-polysaccharide (common to all 91 serotypes) in urine by immunochromatography
- Sensitivity: 50-80%; Specificity: >90%
- Useful when cultures cannot be obtained in time or antibiotics already started
- C-polysaccharide also detectable in CSF
6. Molecular Methods (PCR/NAAT)
- Highly sensitive and specific; unaffected by prior antibiotic use
- Detects multiple pathogens (bacteria + viruses) from a single respiratory sample
- Increasingly standard of care
7. Imaging
- Chest X-ray: Homogeneous lobar or segmental alveolar infiltrate; air bronchograms (airways visible against background of fluid-filled alveoli) - characteristic; small pleural effusion common
- CT chest: Better defines complications (abscess, empyema, adenopathy)
- Lung ultrasound: Shows subpleural consolidation, hepatization pattern
8. Blood Tests
- CBC: Leukocytosis with left shift (neutrophilia + band forms); leukopenia = poor prognosis
- Elevated CRP, ESR, procalcitonin
TREATMENT
Start empirically as soon as possible:
| Clinical Setting | Treatment |
|---|
| Outpatient (mild, non-severe) | Amoxicillin 500mg-1g TID; OR Azithromycin (low resistance area); OR Doxycycline |
| Hospitalized (non-ICU) | IV Ceftriaxone or Ampicillin-sulbactam + Azithromycin |
| Hospitalized (ICU/severe) | IV Beta-lactam (ceftriaxone/cefotaxime) + Azithromycin OR respiratory fluoroquinolone monotherapy (levofloxacin/moxifloxacin) |
| Confirmed penicillin-sensitive | Penicillin G IV (drug of choice) or oral amoxicillin |
| Penicillin allergy (mild) | Third-generation cephalosporin |
| Penicillin allergy (anaphylaxis) | Respiratory fluoroquinolone (levofloxacin/moxifloxacin) |
| Drug-resistant S. pneumoniae | Vancomycin + ceftriaxone; or respiratory fluoroquinolone |
Duration: 5 days if clinical improvement within 72-96 hours.
Prevention: PCV13 (conjugate) + PPSV23 (polysaccharide) vaccines for elderly, immunocompromised, and asplenic patients; Hib vaccine for children.
PART 2: HAEMOPHILUS INFLUENZAE PNEUMONIA
DEFINITION
Pneumonia caused by Haemophilus influenzae, a small pleomorphic Gram-negative coccobacillus requiring X factor (hemin) and V factor (NAD) for growth. It causes predominantly bronchopneumonia (patchy lobular consolidation) rather than true lobar pneumonia. Since widespread Hib vaccination, most pneumonia is caused by non-typeable (non-encapsulated) strains, predominantly in adults with underlying lung disease.
MICROBIOLOGY
- Morphology: Small (0.3-0.5 x 1.5 µm), pleomorphic Gram-negative rods (coccobacilli to long filaments)
- Capsule: Type b capsule contains polyribosylribitol phosphate (PRP) - main virulence factor; 6 capsular types (a-f); non-typeable strains lack a capsule
- Growth requirements: Requires both X factor (hemin, heat-stable) and V factor (NAD, heat-labile) - hence grows on chocolate agar (but not plain blood agar where V-factor inhibitors persist)
- Satellite phenomenon: Grows as tiny satellite colonies around S. aureus on plain blood agar (S. aureus lyses RBCs to release X factor and excretes NAD as V factor)
- Facultative anaerobe (under anaerobic conditions does not require X factor)
PATHOGENESIS
Risk groups
- Adults with COPD (most important) - H. influenzae is the most common bacterial cause of acute COPD exacerbations
- Smokers (damaged mucociliary escalator)
- Diabetics, patients with congestive heart failure
- Elderly patients
- Children (pre-vaccine era): Hib caused meningitis, epiglottitis, pneumonia in children <5 years
Mechanism
- Organisms colonize oropharynx, then descend to lower respiratory tract
- Non-typeable strains use adhesins (Hap, pili, OMP P2, P5) to attach to damaged respiratory epithelium
- IgA protease cleaves secretory IgA
- Lipooligosaccharide (LOS/endotoxin) triggers inflammatory cascade
- Dense fibrin-rich exudates containing neutrophils plug the smaller bronchi
- Consolidation is usually lobular and patchy (bronchopneumonia) but may become confluent and involve an entire lobe
CLINICAL MANIFESTATIONS
- Onset: subacute to acute
- Fever, productive cough with purulent sputum
- Pleuritic chest pain (less prominent than pneumococcal)
- Tachypnea, breathlessness
- Signs of consolidation on examination
- Often follows a viral upper respiratory tract infection (secondary bacterial pneumonia)
- In children (Hib): high-mortality pneumonia; descending laryngotracheobronchitis with airway obstruction from fibrin-rich exudate plugging small bronchi
SUPPURATIVE COMPLICATIONS
- Pleural effusion and empyema - especially with Hib in children
- Bacteremia - leads to metastatic infections
- Lung abscess - less common
- In children (Hib, pre-vaccine era) - hematogenous spread to:
- Meningitis (commonest cause of bacterial meningitis in children <5 years, pre-vaccine)
- Epiglottitis (supraglottitis) - life-threatening airway emergency
- Septic arthritis
- Pericarditis, cellulitis (orbital, buccal), osteomyelitis
NON-SUPPURATIVE COMPLICATIONS
- COPD exacerbations (chronic recurrent inflammation)
- Pyelonephritis, cholecystitis, endocarditis (predisposed adults, rare)
LABORATORY DIAGNOSIS
1. Specimen Collection
- Sputum (from lower airways, minimizing oral contamination)
- Blood cultures (2 sets before antibiotics)
- CSF + blood if meningitis suspected
- Direct needle aspiration for sinusitis/otitis
2. Gram Stain
- Gram-negative coccobacilli (small rods ranging from coccobacilli to long pleomorphic filaments)
- Detected in >80% of CSF in untreated Hib meningitis
- Useful for rapid diagnosis in pneumonia and arthritis
3. Culture
- Media: Chocolate agar - essential; X and V factors are released by heated RBCs and V-factor inhibitors destroyed; incubate at 37°C in 5-10% CO2
- Colonies: 1-2 mm, smooth, opaque after 24 hours
- Satellite phenomenon on plain blood agar around S. aureus colonies (diagnostic clue)
- Blood cultures: growth often delayed (commercial media may not have optimal X+V factor concentrations)
4. Identification
- X and V factor requirement: Spot tests with X, V, and X+V disks on factor-free media; H. influenzae grows only around X+V disk
- Biotype determination by biochemical tests
5. Antigen Detection (for Hib only)
- Latex particle agglutination detects PRP capsular antigen in CSF and urine
- Detects <1 ng/mL of PRP
- Limitation: Only detects type b; not useful for non-typeable strains (now more common)
6. Molecular Methods
- PCR detects H. influenzae from respiratory specimens; useful after antibiotic treatment
7. Imaging
- Patchy bilateral or unilateral bronchopneumonia
- May show segmental/lobar consolidation
- Spherical pneumonia possible in children (rounded edges; due to exudate spread through pores of Kohn)
TREATMENT
| Strain | Treatment |
|---|
| Ampicillin-sensitive (beta-lactamase negative) | Ampicillin IV or oral amoxicillin |
| Beta-lactamase producing strains (~30-40%) | Amoxicillin-clavulanate oral; Ampicillin-sulbactam IV |
| Severe / hospitalized | Ceftriaxone or Cefotaxime IV |
| Meningitis (Hib) | Ceftriaxone (drug of choice); dexamethasone as adjunct |
| COPD exacerbation | Amoxicillin-clavulanate, doxycycline, or azithromycin |
| Multidrug resistant | Fluoroquinolone (levofloxacin) or carbapenem |
Resistance mechanism: Beta-lactamase production (TEM-1 type) - the main mechanism in ~30-40% of strains. Always test susceptibility.
Prevention: Hib conjugate vaccine - has nearly eliminated invasive Hib disease in children; does not protect against non-typeable strains.
PART 3: ATYPICAL PNEUMONIA
DEFINITION
Atypical pneumonia is a clinical syndrome of pneumonia caused by organisms that:
- Cannot be seen on Gram stain (intracellular, lack cell walls, or stain poorly)
- Do not grow on standard bacteriologic media
- Are resistant to beta-lactam antibiotics
- Produce a milder, more indolent clinical picture ("walking pneumonia")
- Cause predominantly interstitial (not alveolar) infiltrates on chest X-ray
The syndrome was first recognized in the 1930s when some patients with pneumonia had milder symptoms than typical S. pneumoniae pneumonia.
CAUSATIVE ORGANISMS
| Category | Organism |
|---|
| Mycoplasma (most common - up to 15% of outpatient CAP) | Mycoplasma pneumoniae |
| Chlamydophila | C. pneumoniae, C. psittaci (psittacosis from birds) |
| Legionella (1-10% of CAP; can be severe) | Legionella pneumophila |
| Rickettsia | Coxiella burnetii (Q fever) |
| Viruses (30% of CAP) | Influenza, adenovirus, RSV, parainfluenza, metapneumovirus, varicella-zoster, measles, EBV, CMV, Hantavirus |
| Fungi | Histoplasma, Blastomyces, Coccidioides, Pneumocystis jirovecii |
| Bioterrorism agents | Francisella tularensis, Yersinia pestis, Bacillus anthracis |
MYCOPLASMA PNEUMONIAE (Primary Atypical Pneumonia) - THE PROTOTYPE
Microbiology
- Smallest free-living self-replicating organism
- NO CELL WALL - hence beta-lactams, vancomycin, and all cell-wall-active antibiotics are completely ineffective
- Pleomorphic (no fixed shape)
- Very slow growing on artificial media; cannot be detected on Gram stain
- Eaton agent (originally thought to be a virus)
Pathogenesis
- Transmitted by respiratory droplets (requires close, prolonged contact)
- Incubation period: 2-3 weeks (long - explains why household/school outbreaks may go unrecognized)
- Community-wide epidemics every 4-7 years
- Organism attaches to respiratory epithelium via P1 adhesin (tip structure)
- Damages ciliated cells - ciliastasis (paralysis of cilia)
- Produces hydrogen peroxide and superoxide radicals - oxidative injury to epithelium
- Triggers intense lymphocytic and monocytic interstitial inflammation (interstitial pneumonitis)
Clinical Manifestations
- Most common in young adults, school-age children, college students, military recruits
- Insidious onset (gradual, over days to a week)
- Malaise, low-grade fever
- Prominent headache - more prominent than in typical pneumonia
- Sore throat (common), minimal coryza
- Dry, non-productive cough - the hallmark; develops progressively over days
- Myalgias, arthralgias
- Patients feel sick but often continue daily activities - hence "walking pneumonia"
Extrapulmonary manifestations (due to immune mechanisms):
- Bullous myringitis (vesicular hemorrhagic blebs on tympanic membrane) - highly characteristic when present
- Skin rashes (maculopapular, erythema multiforme)
- Ear pain, otitis media
SUPPURATIVE COMPLICATIONS
- Small pleural effusion (uncommon)
- Secondary bacterial superinfection
- Lung abscess (very rare)
NON-SUPPURATIVE (EXTRAPULMONARY) COMPLICATIONS
(Immune-mediated, not due to direct bacterial invasion)
- Cold agglutinin hemolytic anemia - most classic complication; IgM anti-I antibodies agglutinate RBCs at 4°C; may cause intravascular hemolysis and jaundice; can precipitate Raynaud's phenomenon
- Stevens-Johnson syndrome / Erythema multiforme - mucocutaneous immune reaction
- Bullous myringitis - hemorrhagic blisters on tympanic membrane
- Neurological complications: Meningoencephalitis, cerebellar ataxia, Guillain-Barre syndrome, transverse myelitis, peripheral neuropathy
- Cardiac: Myocarditis, pericarditis, complete heart block (rare)
- Gastrointestinal: Hepatitis, nausea/vomiting/diarrhea, pancreatitis (rare)
- Reactive arthritis
- Glomerulonephritis (rare, immune-complex mediated)
LABORATORY DIAGNOSIS OF ATYPICAL PNEUMONIA
1. Chest X-Ray
- Interstitial infiltrates - bilateral, peribronchial, reticular pattern; "shaggy heart" border
- X-ray-clinical dissociation - X-ray looks much worse than the patient appears clinically (classic teaching point)
- Usually unilateral lower lobe but may be bilateral
- Small pleural effusion in some cases
2. Cold Agglutinin Test (Mycoplasma-specific pointer)
- Cold agglutinins = IgM antibodies against the I antigen on human group O RBCs; agglutinate at 4°C, dissolve at 37°C
- Positive in ~50-70% of Mycoplasma pneumonia cases
- Bedside test: Blood in a glass tube, put in ice bucket for 2-3 minutes - visible agglutination = positive; re-warm in hand and agglutinate dissolves = cold agglutinin confirmed
- Significant titer: ≥1:32; highly suggestive: ≥1:64
- Not specific - can be positive in EBV, CMV, adenovirus, influenza
3. Serology
- Complement Fixation (CF) test: Fourfold or greater rise in CF antibody titer between acute serum (day 1) and convalescent serum (2-3 weeks later) is diagnostic
- ELISA: Detection of specific IgM (acute infection; appears at 7-10 days, peaks at 3-4 weeks) and IgG (past infection or convalescence)
- Paired serology is confirmatory but retrospective
4. Culture
- Impractical clinically - organisms grow on SP4 medium (special broth/agar) or Hayflick medium over weeks
- Colonies show "fried-egg" appearance under microscope
- Rarely done in routine diagnosis
5. PCR / Molecular Methods (Preferred)
- Most sensitive and specific
- Detects Mycoplasma DNA from nasopharyngeal swab, sputum, or BAL
- Can simultaneously detect Chlamydophila, Legionella, and respiratory viruses
- Rapid (hours); unaffected by prior antibiotic therapy
- Increasingly the standard of care for atypical pneumonia
6. Legionella-Specific Tests
- Urinary antigen test - detects L. pneumophila serogroup 1 (sensitivity 70-90%, specificity >99%); rapid, reliable; test of choice for Legionella
- Culture: BCYE (buffered charcoal yeast extract) agar - specific for Legionella; takes 3-5 days
- DFA (Direct Fluorescent Antibody) test on sputum/BAL
7. Chlamydophila
- Micro-immunofluorescence (MIF) test - reference standard for serology
- PCR from respiratory specimens
TREATMENT OF ATYPICAL PNEUMONIA
| Organism | First-line | Duration |
|---|
| Mycoplasma pneumoniae | Azithromycin 500mg day 1, then 250mg days 2-5; OR Doxycycline 100mg BD | 5 days (azithromycin); 10-14 days (doxy) |
| Chlamydophila pneumoniae | Doxycycline 100mg BD OR Azithromycin | 10-14 days |
| Chlamydophila psittaci (psittacosis) | Doxycycline 100mg BD (drug of choice) | 14-21 days |
| Legionella pneumophila | Azithromycin IV/oral OR Levofloxacin 750mg OD | 5-10 days (azithromycin); 7-10 days (fluoroquinolone) |
| Coxiella burnetii (Q fever) | Doxycycline 100mg BD | 14 days |
Key principle: Beta-lactams are completely INEFFECTIVE for atypical pneumonia (no cell wall target for Mycoplasma; intracellular location protects Chlamydophila; Legionella is intracellular).
For empirical CAP therapy where atypical organisms must also be covered: fluoroquinolones (levofloxacin, moxifloxacin) cover both typical and atypical organisms.
COMPREHENSIVE COMPARISON TABLE
| Feature | Lobar Pneumonia (S. pneumoniae) | H. influenzae Pneumonia | Atypical Pneumonia (Mycoplasma) |
|---|
| Causative agent | S. pneumoniae (Gram+ diplococci) | H. influenzae (Gram- coccobacilli) | M. pneumoniae (no cell wall) |
| Pattern | Lobar consolidation | Bronchopneumonia (patchy, lobular) | Interstitial infiltrate |
| Onset | Sudden, explosive | Subacute to acute | Insidious, gradual |
| Sputum | Rusty/blood-tinged, purulent | Purulent, greenish-yellow | Dry, scanty, non-productive |
| Pleuritic pain | Prominent | Less prominent | Mild or absent |
| X-ray | Homogeneous lobar infiltrate, air bronchograms | Patchy lobular consolidation | Interstitial/peribronchial; worse than clinical findings |
| Gram stain | Gram+ lancet-shaped diplococci with halo | Gram- coccobacilli to pleomorphic rods | Not visible on Gram stain |
| Culture media | Blood/chocolate agar + CO2 | Chocolate agar only (X+V factors needed) | SP4/Hayflick medium; rarely cultured |
| Key lab test | Gram stain + culture; urinary antigen; Quellung | Chocolate agar culture; satellite phenomenon; X+V factor requirement | Cold agglutinins; PCR; serology (IgM ELISA) |
| Key suppurative complication | Empyema, lung abscess, bacteremia, pericarditis | Empyema; meningitis (Hib children) | Pleural effusion (small), rare abscess |
| Key non-suppurative complication | Meningitis, endocarditis, septic arthritis, cardiovascular events | Meningitis/epiglottitis (Hib pre-vaccine) | Cold agglutinin hemolytic anemia, Stevens-Johnson syndrome, neurological |
| Treatment | Penicillin G / Amoxicillin; ceftriaxone; fluoroquinolone | Amoxicillin-clavulanate; ceftriaxone (beta-lactamase producers) | Azithromycin or Doxycycline (NO beta-lactams) |
| Vaccine | PCV13 + PPSV23 | Hib conjugate vaccine (children) | None available |
Sources consulted:
- Jawetz Melnick & Adelberg's Medical Microbiology 28e
- Robbins & Cotran Pathologic Basis of Disease (Robbins, Kumar, Abbas)
- Goldman-Cecil Medicine International Edition
- Harrison's Principles of Internal Medicine 22e (2025)
- Fishman's Pulmonary Diseases and Disorders
- Medical Microbiology 9e (Murray, Rosenthal, Pfaller)